🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🫘😶‍🌫️Uremic Encephalopathy doi.org/10.1016/j.kint…

Congratulations to Dr Ashley Giourdas, post-doctoral fellow in The Lim Lab IU Nephrology and Hypertension who was just awarded the Indiana CTSI T32 Fellowship! Dr Giourdas will be studying CV functional and structural alterations in patients with diabetic CKD.

Why does tirzepatide have a more tolerable gastrointestinal side effect profile than semaglutide? 🤢 GIP agonism coupled with GLP1 receptor agonism decreases gastrointestinal side effects. 🤲 In a study of a long-acting GIP added to liraglutide attenuated GI side effect rates

We are honored to receive the award for growth in #HomeHemodialysis. This achievement reflects the exceptional commitment of our nursing team to advancing patient care. During #NursesWeek, we proudly celebrate their leadership, expertise, and dedication.IU Nephrology and Hypertension #DaVita

C3G and Ig-MPGN—treatment standard doi.org/10.1093/ndt/gf… ➡️The authors review the current standards of treatment and discuss novel developments in the pathophysiology, diagnosis, outcome prediction and management of C3G and Ig-MPGN

👉Benefits of SGLT2 inhibitors in different settings doi.org/10.3390/cells1…

Comparative Effectiveness of GLP1-RA vs SGLT2i in Preventing Chronic Kidney Failure and Mortality in people with T2 diabetes & CKD SGLT2i more favourable for kidney outcomes ajkd.org/article/S0272-…

What % reduction in uACR are you expecting with the combination of empagliflozin & finerenone in type 2 diabetes & CKD at Day 180, as the #CONFIDENCE trial results are presented 5 June at #ERA25?

🚨 Applications now open for the 2025–2026 Dr. Li-Li Hsiao Leadership Fellowship! - For nephrology & postdoc fellows - Leadership training, $2.5K travel stipend, podium presentation, & mentorship Deadline: Aug 1, 2025 Download application form here: drive.google.com/file/d/1WffOb7…

Combination therapy as a new standard of care in CKD - multiple trials testing new therapies in combo with SGLT2i - ARCTIC/PACIFIC trials: Baxdrostat/dapa vs. dapa - EASi-KIDNEY: Vicadrostat/empa vs. empa - ZENITH-HP: Zibotentan/dapa vs. dapa doi.org/10.1093/ndt/gf… #ERA25

“It is absolutely vital that NIH investments are geographically dispersed. The way we combat scientific groupthink is by empowering researchers across the country, no matter where they are, to have a great opportunity if they have great ideas for NIH funding.” - Jay Bhattacharya, MD, PhD

ASN's journals recognize the next generation of nephrologists by awarding trainee prizes at ASN #KidneyWk. Submission eligibility for the 2025 competition ends June 16, 2025, 11:59 PM ET. $750 cash prize could be yours. Learn more: kidney.pub/traineeprize

Today, I’m proud to introduce a revolutionary pathway to drug approvals that will significantly accelerate the delivery of crucial treatments to the American public. I'm committed to fostering innovation that saves lives. The National Priority Voucher program brings the agility

News: FDA halts new clinical trials that export Americans’ cells to foreign labs in hostile countries for genetic engineering nih.gov/news-events/ne…

We’ve announced a new pilot program that can slash the FDA’s drug review time from 10 to 12 months to just 1-2 months. The new Commissioner National Priority Voucher program is designed to bring more cures and meaningful treatments to the American public. For more than a

The oral non-peptide GLP-1 agonist space is quickly filling up #ADA2025 #ADASciScessions

This is the ECON study, an intensive cross-over study examining in-center HD patients by Cardiopulmonary Exercise Testing (CPET) where we demonstrated: - elevated VE/VCO2, an index of pulmonary vascular resistance and right sided cardiac dysfunction after 3-day interdialytic